INT226492

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.28
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 11
Total Number 11
Disease Relevance 7.17
Pain Relevance 2.04

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (IL13) extracellular space (IL13) extracellular region (IL13)
cell-cell signaling (IL13) cytoplasm (IL13)
Anatomy Link Frequency
blood 3
nasal 1
immune system 1
basophils 1
mast cells 1
IL13 (Homo sapiens)
Pain Link Frequency Relevance Heat
cytokine 446 100.00 Very High Very High Very High
chemokine 97 100.00 Very High Very High Very High
Inflammation 434 95.40 Very High Very High Very High
agonist 87 94.80 High High
tolerance 7 89.52 High High
Inflammatory response 32 82.00 Quite High
antagonist 140 72.12 Quite High
aspirin 4 68.08 Quite High
withdrawal 18 61.68 Quite High
Inflammatory mediators 12 50.00 Quite Low
Disease Link Frequency Relevance Heat
Asthma 1333 99.96 Very High Very High Very High
Eosinophilia 105 99.46 Very High Very High Very High
Rhinitis 77 99.20 Very High Very High Very High
Cancer 18 97.84 Very High Very High Very High
INFLAMMATION 476 95.40 Very High Very High Very High
Disease 164 95.24 Very High Very High Very High
Hyperplasia 39 94.56 High High
Metaplasia 24 93.84 High High
Recurrence 8 91.64 High High
Pneumonia 29 91.12 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Concentrations of IL13, a Th2-associated cytokine, and CCL11/Eotaxin, a Th2-associated chemokine, were suppressed in sera from FP compared to controls (IL13) and AFP (IL13 and CCL11) sera (Figure 4B and Additional File 4, Table S3).
Negative_regulation (suppressed) of IL13 associated with chemokine and cytokine
1) Confidence 0.28 Published 2010 Journal BMC Pediatr Section Body Doc Link PMC2944328 Disease Relevance 0.36 Pain Relevance 0.61
It is unclear if there is a problem with the specific monoclonal antibodies that have been developed or if there is too much redundancy in the immune system such that inhibiting either IL-4 or IL-13 is insufficient.
Negative_regulation (inhibiting) of IL-13 in immune system
2) Confidence 0.24 Published 2010 Journal Allergy, Asthma & Immunology Research Section Body Doc Link PMC2946700 Disease Relevance 0.51 Pain Relevance 0.03
High levels of IL-4, IL-5 and IL-13 mRNAs, peripheral blood eosinophil count and serum IgE level decreased after surgery and radiation and continued to decrease during cyclosporine therapy.
Negative_regulation (decreased) of IL-13 in blood
3) Confidence 0.14 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2846923 Disease Relevance 0.79 Pain Relevance 0.15
High levels of IL-4, IL-5 and IL-13 mRNAs, peripheral blood eosinophil count and serum IgE level decreased after surgery and radiation and continued to decrease during cyclosporine therapy.
Negative_regulation (decrease) of IL-13 in blood
4) Confidence 0.14 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2846923 Disease Relevance 0.81 Pain Relevance 0.15
These data support the potential utility of a dual IL-4 and IL-13 oligonucleotide inhibitor in asthma, and suggest that local inhibition of IL-4R?
Negative_regulation (inhibitor) of IL-13 associated with asthma
5) Confidence 0.10 Published 2008 Journal J Occup Med Toxicol Section Body Doc Link PMC2259400 Disease Relevance 1.01 Pain Relevance 0.22
Interestingly, the treatment of children with allergic rhinitis with montelukast induces a significant decrease of nasal lavage IL-4 and IL-13 and a significant increase of IFN-?
Negative_regulation (decrease) of IL-13 in nasal associated with rhinitis
6) Confidence 0.07 Published 2008 Journal J Occup Med Toxicol Section Body Doc Link PMC2259400 Disease Relevance 0.87 Pain Relevance 0.41
Blocking IL-13, but not IL-4, in animal models of asthma prevents the development of airway hyperresponsiveness after allergen, despite a strong eosinophilic response [121,200,201].
Negative_regulation (Blocking) of IL-13 associated with asthma and rhinitis
7) Confidence 0.07 Published 2008 Journal J Occup Med Toxicol Section Body Doc Link PMC2259400 Disease Relevance 1.20 Pain Relevance 0.15
Interestingly, expression of GATA-3, CCR3, -4, -8, and ST2L, and the generation of blood eosinophilia, is intact in mice doubly deficient in both IL-4 and IL-13 [304].
Negative_regulation (deficient) of IL-13 in blood associated with eosinophilia
8) Confidence 0.07 Published 2008 Journal J Occup Med Toxicol Section Body Doc Link PMC2259400 Disease Relevance 0.22 Pain Relevance 0.11
Recent studies of in vitro rapid antigen desensitizations implicate mast cells and basophils as cellular targets, as well as syk, a signal transducing molecule, and signal transducer and activator of transcription 6 (STAT6), which is responsible for the transcription of interleukin (IL)-4 and IL-13.29 Rapid desensitization results in patients achieving the target total dose of the drug through rapidly escalating doses usually within 24 hours, slow desensitization results in patients achieving the total target dose within a few days to weeks.
Negative_regulation (desensitization) of IL-13 in basophils
9) Confidence 0.05 Published 2010 Journal Allergy, Asthma & Immunology Research Section Body Doc Link PMC2846744 Disease Relevance 0.55 Pain Relevance 0.04
Significant decreases in IL-8, IL-10, IL-13 and VEGF secretion were observed compared with untreated controls.
Negative_regulation (decreases) of IL-13
10) Confidence 0.03 Published 2009 Journal Part Fibre Toxicol Section Body Doc Link PMC2676242 Disease Relevance 0.31 Pain Relevance 0.12
Recent studies of in vitro rapid antigen desensitizations implicate mast cells and basophils as cellular targets, as well as syk, a signal transducing molecule, and signal transducer and activator of transcription 6 (STAT6), which is responsible for the transcription of interleukin (IL)-4 and IL-13.29 Rapid desensitization results in patients achieving the target total dose of the drug through rapidly escalating doses usually within 24 hours, slow desensitization results in patients achieving the total target dose within a few days to weeks.
Negative_regulation (desensitization) of IL-13 in mast cells
11) Confidence 0.02 Published 2010 Journal Allergy, Asthma & Immunology Research Section Body Doc Link PMC2846744 Disease Relevance 0.55 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox